1-ethyl-2,3-dioxopiperazine (P 32)

04/01/2008 - "Improvement in Knee Society knee score and flexion was greater for women (P = .006), and there were equal pain relief and walking improvements for both sexes (P < .32). "
07/01/2012 - "At 2 years after initial presentation, there was no significant relationship between elbow pain and medial epicondylar fragmentation (P = .32). "
06/01/2011 - "In the RSO group (n = 99), pain relief by VAS from 6 ± 2 before to 5 ± 3, 4 ± 2, 3 ± 2 and 4 ± 2 at 1, 3, 6, 12 months after RSO was documented (Y-90 group: 6 ± 2 to 3 ± 2; P-32: 5 ± 2 to 3 ± 2, Re-188: 7 ± 2 to 4 ± 2 before vs. 6 months after therapy, respectively). "
10/01/2008 - "Median pain scores were low and similar in the occlusive (0.90; IQR, 0.29-2.34) and the gauze (0.64; IQR, 0.22-1.95) groups (P = .32). "
11/01/2002 - "There was no significant difference in patient-reported pain scores for overall pain perioperatively (P =.47, Wilcoxon rank sum test) and the worst pain perceived during surgery (P =.32, Wilcoxon rank sum test). "

07/01/1994 - "The use of P-32 as an adjuvant for Stage I and II epithelial carcinoma of ovary has been found to be effective in prior GOG trials. "
01/01/2007 - "No difference was observed in survival between base of tongue and tonsillar carcinoma (P = .32). "
10/01/1994 - "Sixteen patients with carcinoma of the ovary who were offered IP P-32 therapy between January 1988 and December 1992 were retrospectively reviewed. "
07/01/1994 - "Use of P-32 in stage III epithelial carcinoma of the ovary."
10/01/1987 - "P-32 was found to be an effective adjuvant treatment in a select group of patients with ovarian carcinoma who were at high risk for intraabdominal recurrence."

07/01/1970 - "[Study of the biological activity of tumors using P 32 (clinical study)]."
12/25/1962 - "[Fundamental studies on the diagnosis of malignant tumors using P-32 deceleration radiation. "
01/01/1960 - "[Comparative microautoradiographic studies with p-32 and Au-198 on bone marrow--and tumor cells]."
03/01/2015 - "The median tumor PFS and overall PFS were 20.8 months and 9.3 months (P = .72) for transarterial chemoembolization plus RF ablation and 21.8 months and 9.2 months for transarterial chemoembolization plus MW ablation (P = .32). "
09/01/2014 - "Despite a significant increase in tumor response at the time of surgery, no differences in 5-year OS (70.6% vs 63.6%, hazard ratio [HR] = 1.24, P=.34) and PFS (63.9% vs 52.0%, HR=1.22, P=.32) were observed. "

09/01/2008 - "The genetic study found that schizophrenia risk for incompatible males was significantly greater than for compatible offspring (p=0.03), while risk for incompatible and compatible females was not significantly different (p=.32). "
07/01/1965 - "[Contribution to the study of I-131 and P-32 dynamics in schizophrenia]."
01/01/1966 - "[Studies on the uptake of P 32 by erythrocytes in patients with schizophrenia and other psychoses]."

09/20/2014 - "No differences were found between arms A and B in 30-day mortality (1.8% v. 2.0%, respectively; P = .81), 3-year PFS (61.2% v. 58.9%, respectively; P = .76), 3-year OS (72.9% v. 75.8%, respectively; P = .32), locoregional failure (19.9% v. 25.9%, respectively; P = .97), or distant metastasis (13.0% v. 9.7%, respectively; P = .08). "
08/01/1983 - "Long-term follow-up is needed to determine the effect of P-32 on the liver and the frequency of hepatic metastases."
07/01/1965 - "[Can the index of P 32 uptake show radiosensitivity of metastases?]."
01/01/1984 - "Relief of pain is obtained in some patients after application of P-32 or Sr-89, intense uptake in the metastases is necessary but does not guarantee successful treatment."
07/01/1959 - "Use of radioactive P-32 in treating skeletal metastases from carcinoma of the prostate."